Verve Therapeutics

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan and Burt A. Adelman in 2018 and is headquartered in Boston, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Verve Therapeutics, Inc. (“Verve” or the “Company”) (NASDAQ: VERV) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Verve securities between August 9, 2022, and April 1, 2024, both dates inclusive (the “Class Period”). Investors have until October 28, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

VERVE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Verve Therapeutics, Inc. and Encourages Investors to Contact the Firm

NEW YORK , Aug. 28, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. in Securities Fraud Lawsuit

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Verve Therapeutics, Inc. (NASDAQ: VERV) securities between August 9, 2022 and April 1, 2024. Verve is a “clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines.

Stockholder Notice: Robbins LLP Informs Stockholders of the Class Action Filed Against Verve Therapeutics, Inc.

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired Verve Therapeutics, Inc. (“Verve” or the “Company”) (NASDAQ: VERV) securities between August 9, 2022 and April 1, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company's investors under the federal securities laws.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Verve Therapeutics, Inc. (VERV)

LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Investors In Verve Therapeutics Inc To Participate In An Investigation Into Potential Securities Law Violations

ATLANTA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Verve Therapeutics, Inc. (“Verve Therapeutics” or “the Company”) (NASDAQ: VERV). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company's business, operations, and prospects, including allegations that: (1) Defendants did not fully disclose the circumstances under which the Heart-1 trial would be halted; and (2) Defendants overstated the potential benefits of its proprietary LNP delivery system.

SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of Verve Therapeutics, Inc. (VERV) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)---- $VERV #VERV--Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Verve Therapeutics investors under the federal securities laws. To join the Verve Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=28262.

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Verve Therapeutics, Inc. – VERV

LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Verve Therapeutics Is Being Looked Into For Securities Fraud By The Schall Law Firm And Stakeholders Are Invited To Help

LOS ANGELES, CA / ACCESSWIRE / August 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Investors To Join An Investigation Into Whether Verve Therapeutics Inc Committed Securities Law Infractions

LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Verve Therapeutics Inc Is Being Inquired Into For Potential Securities Law Violations And The Schall Law Firm Is Seeking Shareholders To Participate

LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Investors In Verve Therapeutics Inc To Join The Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Inquiring Into Verve Therapeutics Inc For Potential Securities Law Violations And Stockholders Are Encouraged To Participate

LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Verve Therapeutics Inc Is Being Investigated By The Schall Law Firm For Possible Securities Fraud And Investors Are Invited To Assist

LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Verve Therapeutics Inc For Potential Securities Law Violations And Seeks Shareholders' Involvement

LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Verve Therapeutics Inc Is Being Investigated By The Schall Law Firm For Possible Securities Violations And Wants Shareholders To Participate

LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Inquiring Into Allegations Against Verve Therapeutics Inc For Securities Violations And Wants Investors To Join

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Allegations Against Verve Therapeutics Inc And Wants Investors To Help

LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Inquiring Into Allegations Against Verve Therapeutics Inc And Seeks Shareholders To Join

LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Verve Therapeutics Inc And Seeks Investors With Losses To Join

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Verve Therapeutics Inc And Invites Investors With Losses To Reach Out

LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Verve Therapeutics Inc And Encourages Investors With Losses To Reach Out

LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Probing Verve Therapeutics Inc And Motivates Investors With Losses To Reach Out

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Verve Therapeutics Inc Is Under Investigation By The Schall Law Firm Which Encourages Investors With Losses To Make Contact

LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Verve Therapeutics Inc Is Being Probed By The Schall Law Firm Which Urges Investors With Losses To Reach Out

NEW YORK, Aug. 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Verve Therapeutics, Inc. (NASDAQ: VERV) on behalf of the company's shareholders. The investigation seeks to determine whether Verve Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.

News for Verve Therapeutics Stock (VERV)